How to appeal a Highmark spinal muscular atrophy denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Highmark-specific note: Operates BCBS in PA (western), WV, DE, NY (western). Owns Allegheny Health Network.

What Highmark's policy requires for spinal muscular atrophy

Cited policy: BCBS Combination / Sequential SMA Disease-Modifying Therapy

Single SMA disease-modifying therapy at a time per most plans. Sequential Zolgensma → Spinraza/Evrysdi maintenance requires medical justification: documented sub-optimal response to gene therapy (CHOP-INTEND plateau, slow milestone gain, 2-copy SMN2 high-risk). Specialist letter from neuromuscular MD.

How Highmark denies spinal muscular atrophy — and how to counter it

Where Highmark pushes back: 1) Combination labeled experimental; 2) Single therapy sufficient; 3) No FDA approval for combination.

Counter-arguments that hold up: Combination/sequential Zolgensma → Spinraza or Evrysdi maintenance is supported by RESTORE registry (Novartis real-world), multiple peer-reviewed case series (Harada 2021; Lee Fay Sansone 2024), Mercuri 2024 consensus reviews, and ASGCT guidance for selected post-gene-therapy plateau or slow responders. Cure SMA real-world data document widespread practice. NOT a label-defying use — gene therapy + SMN2 splicer have distinct mechanisms; SMN2 modulator addresses residual gene therapy under-expression. Submit specific motor-function trajectory, SMN2 copy number, and neuromuscular specialist rationale.

What Highmark typically denies for spinal muscular atrophy

Across Highmark's commercial and Medicare books, denials cluster around a small number of patterns. For spinal muscular atrophy, expect:

• Prior auth on biologics
• PA on advanced imaging
• OON balance bills

Treatments most often denied in this category

These are the spinal muscular atrophy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Spinraza (nusinersen)
• Evrysdi (risdiplam)
• Zolgensma (onasemnogene)
• Combination/sequential
• Switching therapy
• BiPAP / NIV

How to submit the appeal to Highmark

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Highmark cited in the denial.
3. File the appeal through Highmark's portal (members: https://www.highmark.com ; providers: https://www.highmark.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In PA, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Highmark's prior-authorization criteria by drug: Highmark PA criteria on ApprovalHelp.